How Inflammaging and Mutant Blood Stem Cells Drive Each Other Into Chronic Disease

Why this matters: Aging drives a convergence of two interconnected pathologies—clonal hematopoiesis of indeterminate potential (CHIP) and chronic low-grade systemic inflammation (inflammaging)—that together dramatically amplify risk for a broad spectrum of chronic diseases. Understanding their bidirectional relationship is critical for developing targeted preventive and therapeutic strategies in an aging global population.

What was studied: This comprehensive review by Hajishengallis and Chavakis synthesizes current molecular, cellular, epidemiological, and translational evidence on how CHIP and inflammaging interact. The authors examine how aging and inflammatory stress impair normal hematopoietic stem cells (HSCs), the molecular mechanisms driving CHIP mutations, lifestyle and biological factors promoting CHIP expansion, and how CHIP-derived immune cells perpetuate and amplify inflammation across multiple organ systems.

Key results: CHIP arises from somatic mutations—most commonly in epigenetic regulators DNMT3A (~40%), TET2 (~25%), and ASXL1—that confer selective expansion advantages to mutant HSC clones. Using ultra-sensitive sequencing, nearly 95% of individuals aged 50–60 carry detectable CHIP mutations. Inflammaging impairs normal HSC self-renewal and skews differentiation toward myeloid lineages, while paradoxically providing a selective growth advantage to CHIP-mutant clones resistant to this inflammatory pressure. CHIP-derived myeloid cells then produce excess IL-1β, IL-6, and TNF, feeding back to worsen systemic inflammation. Beyond cardiovascular disease—the most strongly linked condition—CHIP is now associated with COPD, chronic kidney disease, chronic liver disease, osteoporosis, rheumatoid arthritis, and periodontitis. Lifestyle factors including smoking (confirmed causal by Mendelian randomization), obesity, unhealthy diet, and chemotherapy/radiation accelerate CHIP via mutagenesis, inflammatory signaling, and selective pressure on DNA damage response gene mutations (PPM1D, TP53). Inherited variants—such as a protective TCL1A promoter polymorphism—modulate CHIP clone growth rates, highlighting a genetic dimension to CHIP susceptibility.

Implications: IL-1 signaling has emerged as a central mediator of both normal HSC dysfunction and CHIP-mutant clone expansion, making it a prime therapeutic target. Canakinumab (IL-1β inhibitor) and other anti-inflammasome agents are under active investigation, especially for TET2-mutant CHIP carriers. A self-sustaining CHIP–inflammaging feedback loop likely contributes to the chronicity of age-related inflammatory diseases, suggesting that early identification and intervention in CHIP carriers could broadly reduce multimorbidity in older adults.

Caveats: Most human CHIP data are cross-sectional and statistically adjusted for age, limiting direct assessment of inflammaging's specific causal contribution to CHIP development. Prospective longitudinal studies are urgently needed to validate reverse causality—that inflammation promotes CHIP expansion—and to establish clinical thresholds for intervention. The clinical significance of very low variant allele frequency clones (below the classical 2% VAF threshold) remains uncertain, though preliminary evidence links even small TET2/DNMT3A clones to worse outcomes in heart failure patients.